ArticleAntimicrobial agents and chemotherapy2021
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Synthesis and antibacterial activity of novel benzodioxin-containing oxazolidinones against M. abscessus.Bioorganic & medicinal chemistry letters · 2025Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- Current Advances in Developing New Antimicrobial Agents Against Non-TuberculousAntibiotics (Basel, Switzerland) · 2025Review
- In Vitro Antimicrobial Activity of Contezolid AgainstMicroorganisms · 2025Article
- Clinical outcomes of contezolid in treating complex tuberculosis: real-world evidence from 11 patients.Journal of thoracic disease · 2025Article
- ThePeerJ · 2025Review
- TBAJ-587, a novel diarylquinoline, is active againstAntimicrobial agents and chemotherapy · 2024Article
- Contezolid-Containing Regimen Successfully Treated Multiple Drug Resistance Mycobacterium Abscessus Complex Infection of Skin: A Case Report and Literature Review.Infection and drug resistance · 2024Article
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Article
- Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2023Article
- Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.Frontiers in pharmacology · 2023Article
- Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid.Frontiers in medicine · 2023Article
- Review
- Novel oxazolidinones harbor potentFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
An evaluation of the anti-Mycobacterium abscessus activity expressed by a novel oxazolidinone, contezolid (MRX-I), toward 12 reference strains and 194 clinical isolates was conducted. Contezolid was active against M. abscessus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.